Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy
| Autor: | Haruhiko, Ozaki, Satoshi, Harada, Toshihisa, Takeuchi, Shinpei, Kawaguchi, Yoshiaki, Takahashi, Yuichi, Kojima, Kazuhiro, Ota, Yasushi, Hongo, Kiyoshi, Ashida, Masahiro, Sakaguchi, Satoshi, Tokioka, Hiroki, Sakamoto, Takahisa, Furuta, Kazunari, Tominaga, Kazuhide, Higuchi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Comparative Effectiveness Research Sulfonamides Polymorphism Genetic Helicobacter pylori Proton Pump Inhibitors Middle Aged Anti-Bacterial Agents Helicobacter Infections Cytochrome P-450 CYP2C19 H(+)-K(+)-Exchanging ATPase Treatment Outcome Breath Tests Drug Resistance Bacterial Potassium Humans Drug Therapy Combination Female Pyrroles Aged |
| Zdroj: | Digestion. 97(3) |
| ISSN: | 1421-9867 |
| Popis: | Phase III study demonstrated that vonoprazan-based Helicobacter pylori eradication therapy achieved higher eradication rate compared with lansoprazole. However, there is no study that evaluated the efficacy of vonoprazan in a large sample in real world. We investigated the eradication rate and safety of vonoprazan-based eradication therapy compared with our randomized control trial using second-generation proton pump inhibitor (PPIs).(First study) A total of 147 patients who have H. pylori infection were randomly assigned to receive either, esomeprazole (EPZ) group and rabeprazole (RPZ) group. (Second study) 1,688 patients who have H. pylori infection underwent primary eradication with triple therapy involving vonoprazan. In both studies, triple therapy with amoxicillin, clarithromycin, and PPI or vonoprazan was performed, and eradication effect was assessed by an urea breath test.(First study) Eradication rate was 77.5% in the EPZ group and 68.4% in the RPZ group; no significant difference was observed between the 2 groups. (Second study) The successful primary eradication rate was 90.8%. There was no severe adverse effect.The eradication rate of vonoprazan-based triple therapy was remarkably higher compared with second-generation PPIs-based triple therapy in real world. Vonoprazan is very likely to become the first option for future eradication therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|